Progenitor Cell Therapy for Neurological Injury
There are currently no reparative therapies for severe neurological injury, including brain injury, spinal cord injury and stroke. Actually, most treatments are designed simply to limit secondary damage. However, pre-clinical data supports the idea that e
- PDF / 6,233,045 Bytes
- 207 Pages / 439.37 x 666.142 pts Page_size
- 91 Downloads / 219 Views
For other titles published in this series, go to http://www.springer.com/series/7896
wwwwwwwwwwwwww
Charles S. Cox, Jr. Editor
Progenitor Cell Therapy for Neurological Injury
Editor Charles S. Cox, Jr. University Texas Medical School at Houston Department of Pediatric Surgery Houston, Texas USA [email protected]
ISBN 978-1-60761-964-2 e-ISBN 978-1-60761-965-9 DOI 10.1007/978-1-60761-965-9 Springer New York Dordrecht Heidelberg London © Springer Science+Business Media, LLC 2011 All rights reserved. This work may not be translated or copied in whole or in part without the written permission of the publisher (Humana Press, c/o Springer Science+Business Media, LLC, 233 Spring Street, New York, NY 10013, USA), except for brief excerpts in connection with reviews or scholarly analysis. Use in connection with any form of information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed is forbidden. The use in this publication of trade names, trademarks, service marks, and similar terms, even if they are not identified as such, is not to be taken as an expression of opinion as to whether or not they are subject to proprietary rights. Printed on acid-free paper Humana Press is part of Springer Science+Business Media (www.springer.com)
Preface
Severe neurological injury, including traumatic brain injury, spinal cord injury, and stroke, can have devastating consequences. There are currently no reparative therapies for neurological injury, with most treatments designed to limit secondary damage. The idea that exogenous stem and progenitor cells have the potential to promote a reparative response to injury is now supported by pre-clinical data, prompting early translational studies using progenitor cell therapies. To that end, this text explores the unique aspects of neurological injury and focuses on the critical translational issues of cell delivery: routes of administration, types of progenitor cells (alone and/or in combination), timing of delivery, and adjuncts to promote cell engraftment/survival/effectiveness. Finally, measuring the effects of transplanted cells and cell tracking is explored in several chapters. Even while compiling this monograph, the paradigms of how cell-based therapeutics affect neurological injury have been changing. Mechanisms that seemed reasonable and well-supported are being re-examined, and this necessarily drives the movement toward various clinical trial plans. The earliest clinical trials are beginning, and as this monograph goes to press, Phase 2 studies in TBI and stroke will begin. The developments in the field may ultimately offer realistic hope for improvement in patients with severe injuries, and the work on these vexing problems will be the key to unlocking future treatments.
v
wwwwwwwwwwwwww
Contents
1 Basics of Stem and Progenitor Cells......................................................... Matthew T. Harting
1
2 Progenitor Cell Tissue Engineering........................
Data Loading...
